Clinical Trial Finds Ozempic Reverses Biological Age by 3.1 Years
By
amichail
9mo ago· 3 min readenNews
65/100
Toasty
Bagelometer↗
Right out the toaster. Reliable, with some real depth.
Score65TypenewsSentimentpositive
Summary
The diabetes drug Ozempic has shown significant anti-aging effects in a clinical trial, reversing biological age by an average of 3.1 years in participants after 32 weeks of treatment. The study, led by Varun Dwaraka, used epigenetic clocks to measure aging, revealing pronounced effects in the inflammatory system and brain. Researchers attribute these benefits to semaglutide's ability to improve fat distribution and reduce inflammation, suggesting potential broader anti-aging applications.
Key quotes
· 4 pulledThe diabetes drug Ozempic has demonstrated remarkable anti-aging effects in the first clinical trial to directly measure its impact on biological aging.
Participants became an average of 3.1 years biologically younger after 32 weeks of treatment.
The study used epigenetic clocks to measure biological aging, showing the most pronounced anti-aging effects in the inflammatory system and brain.
Researchers believe the anti-aging effects stem from semaglutide's ability to improve fat distribution and reduce inflammation.
- A randomized controlled trial of 108 people with HIV-associated lipohypertrophy found that weekly Ozempic treatment for 32 weeks reversed biological age by an average of 3.1 years.
- The study used epigenetic clocks to measure biological aging, showing
